AI-powered molecules to treat pulmonary embolismNovember 17, 2021
San Francisco-based Viz.ai pharma announced that the company is launching its artificial intelligence-based molecules which allow for better management of pulmonary embolism and aortic disease.
The molecules use deep learning to identify the disease. Medical researchers have expressed hope that the new device will reduce the diagnosis time and save lives under critical conditions. The company said that the new AI molecules will identify the suspected pulmonary embolism in under 2 minutes.
Pulmonary embolism is mostly caused by blood clots that travel to the lungs and block the pathway in the pulmonary arteries.